Seltorexant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

4 competitors in Depressive Disorder, Major

#DrugCompanyPhaseTrials

1

Spravato

WWim Janssens

Phase 3

12

Ulotaront

IIntra-Cellular Therapies, Inc.

Phase 3

13

Brenipatide

Eli Lilly

Phase 3

24

Psilocybin

COMPASS Pathways

Phase 3

15

Seltorexant

Johnson & Johnson

Phase 3

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Major Depressive Disorder5 trials

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Completed·Johnson & Johnson·Phase 3·NCT04513912·757 enrolled

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Terminated·Johnson & Johnson·Phase 3·NCT04532749·212 enrolled

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Terminated·Johnson & Johnson·Phase 1·NCT04951609·31 enrolled

Show 2 more trials

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

Completed·Johnson & Johnson·Phase 3·NCT04533529·588 enrolled

A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder

Completed·Johnson & Johnson·Phase 1·NCT04451187·63 enrolled

ART3 trials

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT03682380·151 enrolled

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT05236868·10 enrolled

A Study of Seltorexant in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT04553042·69 enrolled

Depressive Disorder, Major2 trials

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant

Recruiting·Johnson & Johnson·Phase 3·NCT07573176·600 enrolled

A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms

Recruiting·Johnson & Johnson·Phase 3·NCT06559306·752 enrolled

Oral1 trial

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Completed·Johnson & Johnson·Phase 1·NCT03438461·49 enrolled

Obstructive Sleep Apnea1 trial

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Completed·Johnson & Johnson·Phase 1·NCT03796026·34 enrolled

3 more indications

Adult1 trial

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

Completed·Johnson & Johnson·Phase 1·NCT03494907·52 enrolled

Alzheimer's Disease1 trial

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Completed·Johnson & Johnson·Phase 2·NCT05307692·88 enrolled

Abuse Potential1 trial

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Completed·Johnson & Johnson·Phase 1·NCT05106153·127 enrolled

Details

Drug Info

Related News